Moderna Drops 11%, ImmunityBio Slide Wakes Biotech Rout
Biotech shares retreat as Moderna slides 11% and ImmunityBio falls, with Sarepta also sinking amid a broad market rot...
When faced with surprise expenses, pause, assess impact, and execute a prepped plan: reallocate, delay nonessential spending, and access the buffer.
10,028 articlesBiotech shares retreat as Moderna slides 11% and ImmunityBio falls, with Sarepta also sinking amid a broad market rot...
In July’s session, AT&T surprised with subscriber growth that outweighed a revenue miss, lifting its stock and offeri...
U.S. equities ended February with sharp moves as a private-credit risk cycle and AI-driven volatility rattled investo...
Bitcoin faced a key test near $74,000 as geopolitical tensions intensified, and BlackRock launched its ETHB ETF, resh...
Nike remains a heavyweight in athletic wear, but its stock has faced pressure. This guide breaks down whether should ...
Three large-cap utilities have pulled back on rate-case concerns and regulatory overhangs. This report grades Edison ...
Kohl's stunned investors with a strong swing in its latest quarterly results, sending the stock higher by double digi...
Bitcoin price craters $60,000 after the May U.S. jobs report, as traders reassess Federal Reserve easing bets. Crypto...
A recently launched active bond fund delivers a 5.18% yield with noticeably less interest-rate risk than long-duratio...
XRP is under renewed pressure after a harsh stretch of declines, with traders weighing the risk of deeper losses agai...
Perplexity’s decision to base its AI tooling on Nvidia’s Vera CPUs over AMD’s x86 chips signals a major shift in the ...
Ethereum struggles to form a durable base as macro uncertainty persists. This ethereum price prediction piece surveys...